Rating History for Neoleukin Therapeutics (NLTX) by Guggenheim

More Stocks Rated by Guggenheim | Latest Ratings for NLTX
Date Analyst Type Rating
(Past)		 PT
(Past)		 Start $
(End $)		 % Chg. Details
1/3/2023 Charles Zhu Downgrade Neutral
(Buy)		 N/A
(N/A)		 0.51
(3.49)		 584.31% Details